<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00215995</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-13426</org_study_id>
    <secondary_id>USFIRB#101525</secondary_id>
    <nct_id>NCT00215995</nct_id>
  </id_info>
  <brief_title>Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas</brief_title>
  <official_title>A Phase II Study of Cisplatin and Irinotecan Induction Chemotherapy, Followed by ZD 1839 (IRESSA) in Adult Patients With Surgically Unresectable and/or Metastatic Esophageal or Gastric Carcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is for patients with esophageal, esophagogastric, or gastric cancer that has&#xD;
      spread to other parts of the body. The purpose of this study is to test the safety and&#xD;
      effectiveness of a new experimental drug called ZD 1839 following initial therapy with two&#xD;
      other chemotherapy drugs, called Irinotecan (CPT-11) and Cisplatin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, non-randomized, multicenter Phase II study designed to evaluate tumor&#xD;
      response rates in patients with surgically unresectable and/or metastatic esophageal,&#xD;
      esophagogastric, and gastric adenocarcinoma or squamous carcinoma. Study schema is as&#xD;
      follows. Patients will receive Irinotecan and Cisplatin on days 1 and 8 every 21 days for a&#xD;
      maximum of 6 cycles of therapy. This is then followed by ZD 1839 (Iressa), which is an oral&#xD;
      pill taken once daily. During the Iressa phase, patients will be evaluated every 6 weeks.&#xD;
      This includes labs, CT scans and physical examination. The exploratory objective of the study&#xD;
      is to examine the correlation between epidermal growth factor receptor (EGFR) expression and&#xD;
      radiographic response to treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Desired Response</measure>
    <time_frame>48 Months</time_frame>
    <description>Response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Participants' Desired Response</measure>
    <time_frame>48 Months</time_frame>
    <description>Response duration in months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants' Time to Disease Progression</measure>
    <time_frame>48 Months</time_frame>
    <description>Time to progression in months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Overall Survival</measure>
    <time_frame>48 Months</time_frame>
    <description>Overall survival from first participant On Treatment to last participant Off Study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Cisplatin, Irinotecan and ZD1839</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>As outlined in Detailed Description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>As outlined in Detailed Description</description>
    <arm_group_label>Cisplatin, Irinotecan and ZD1839</arm_group_label>
    <other_name>Platinol</other_name>
    <other_name>Platinol-AQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>As outlined in Detailed Description</description>
    <arm_group_label>Cisplatin, Irinotecan and ZD1839</arm_group_label>
    <other_name>Camptosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD 1839</intervention_name>
    <description>As outlined in Detailed Description</description>
    <arm_group_label>Cisplatin, Irinotecan and ZD1839</arm_group_label>
    <other_name>Iressa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic confirmation of esophageal carcinoma (squamous or adenocarcinoma) or&#xD;
             gastric adenocarcinoma.&#xD;
&#xD;
          -  Surgically unresectable disease and/or metastatic disease.&#xD;
&#xD;
          -  No prior chemotherapy therapy.&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks.&#xD;
&#xD;
          -  Patients must have the ability to take and retain oral medications.&#xD;
&#xD;
          -  Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0,&#xD;
             1, or 2 (Karnofsky Performance Status [KPS] ≥50%).&#xD;
&#xD;
          -  Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST) criteria and computerized tomographic scan performed within 28 days prior to&#xD;
             registration.&#xD;
&#xD;
          -  Organ system function assessed within 7 days prior to registration and within the&#xD;
             following parameters:&#xD;
&#xD;
               -  Absolute neutrophil count ≥1500/mL;&#xD;
&#xD;
               -  Platelet count ≥100,000/mL;&#xD;
&#xD;
               -  Hemoglobin level ≥10.0 gm/dL;&#xD;
&#xD;
               -  Serum creatinine ≤1.5 x IULN (Institutional Upper Limits of Normal); OR Measured&#xD;
                  creatinine clearance ≥60 mL/min;&#xD;
&#xD;
               -  AST (SGOT) or ALT (SGPT) ≤ 2.5 x IULN (unless the liver is involved by tumor, in&#xD;
                  which case it must be ≤5.0 x IULN);&#xD;
&#xD;
               -  Total bilirubin ≤1.5 x IULN.&#xD;
&#xD;
          -  Understanding of the subject of the potential and unknown teratogenic risk, as well as&#xD;
             their willingness to practice birth control. Should a pregnancy occur while a subject,&#xD;
             either father or mother, is receiving study medication, the subject should inform the&#xD;
             doctor immediately.&#xD;
&#xD;
          -  Aged 18 years or older&#xD;
&#xD;
          -  Provision of written informed consent&#xD;
&#xD;
          -  For patients with locally advanced disease, subjects must be evaluated by a radiation&#xD;
             oncologist prior to study entry, and judged that radiation therapy is not indicated in&#xD;
             the subjects therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with EGFR-inhibiting agents, chemotherapy, or radiotherapy for&#xD;
             esophagogastric carcinomas.&#xD;
&#xD;
          -  Patients must not be receiving any other investigational agents. Use of erythropoietin&#xD;
             is allowable. Secondary prophylaxis with granulocyte colony stimulating factor (G-CSF)&#xD;
             (Filgrastim) is allowable. The use of granulocyte-macrophage colony stimulating factor&#xD;
             (GM-CSF) (Sargramostim) is not allowed on this protocol.&#xD;
&#xD;
          -  Uncontrolled brain metastases.&#xD;
&#xD;
          -  Patients must not have uncontrolled intercurrent illness at the time of registration&#xD;
             including, but not limited to, ongoing or active infection, symptomatic congestive&#xD;
             heart failure, unstable angina, pectoris, cardiac arrhythmia, or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements.&#xD;
&#xD;
          -  Patients must not have current New York Heart Association Class III or IV heart&#xD;
             disease.&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Pregnant or breast-feeding women.&#xD;
&#xD;
          -  Patients who have had prior malignancies, except non-melanoma skin cancer (basal or&#xD;
             squamous cell carcinoma) are not eligible for this study; unless greater than 5 years&#xD;
             has passed since the event.&#xD;
&#xD;
          -  Known severe hypersensitivity to ZD 1839 or any of the excipients of this product.&#xD;
&#xD;
          -  Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital,&#xD;
             or St. John's Wort.&#xD;
&#xD;
          -  Treatment with a non-approved or investigational drug within 30 days before Day 1 of&#xD;
             trial treatment.&#xD;
&#xD;
          -  Incomplete healing from previous oncologic or other major surgery.&#xD;
&#xD;
          -  Serum creatinine level greater than Common Toxicity Criteria (CTC) grade 2.&#xD;
&#xD;
          -  Any evidence of clinically active interstitial lung disease. Subjects with chronic&#xD;
             stable radiographic changes who are asymptomatic need not be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Garrett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ponce School of Medicine</name>
      <address>
        <city>Ponce</city>
        <zip>00732</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Puetro Rico Cancer Center</name>
      <address>
        <city>San Juan</city>
        <zip>00936-5067</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org</url>
    <description>Moffiitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>September 19, 2005</study_first_submitted>
  <study_first_submitted_qc>September 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>January 12, 2012</last_update_submitted>
  <last_update_submitted_qc>January 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>esophageal cancer</keyword>
  <keyword>esophagogastric cancer</keyword>
  <keyword>gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

